Potentiation of erythropoiesis
US5032507A · kind A · utility
19Cited by
0References
3Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 13, 1987 |
| Grant date | Jul 16, 1991 |
| Priority date | — |
| Expiry date | Nov 13, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for modulating the rate of erythropoiesis in human hematopoietic progenitor cells. FRP is found to be an efficacious potentiator of, and inhibin a suppressor of, erythropoietin-induced differentiation. FRP and inhibin are shown to be functional antagonists of each other, and thus represent an effective means for modulating erythropoiesis in a number of disease states which are directly caused by or associated with an abnormal rate of erythropoiesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.